AlgoHunter Logo

AlgoHunter - Stock Profile

Login

CLYM

$6.9258

$

Biotechnology

Climb Bio, Inc., a biotechnology company, focuses on developing therapies for autoimmune-driven inflammatory diseases. It develops budoprutug, an anti-CD19 monoclonal antibody for various autoimmune diseases, including systemic lupus erythematosus and lupus nephritis, immune thrombocytopenia, and membranous nephropathy. The company was formerly known as Eliem Therapeutics, Inc. and changed its name to Climb Bio, Inc. in October 2024. Climb Bio, Inc. was incorporated in 2018 and is headquartered in Wilmington, Delaware.

Next Earnings

2026-02-25

Beta

-0.147

Average Volume

Market Cap

Last Dividend

CIK

0001768446

ISIN

US28658R1068

CUSIP

CEO

Aoife Brennan BCh MMSc

Sector

Healthcare

Industry

Biotechnology

Full Time Employees

17

IPO Date

2021-08-10

Status

Active

Latest News

Title Headline Publisher Date
Climb Bio to Present at Upcoming Investor Conferences WELLESLEY HILLS, Mass., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical stage biotechnology company developing therapeutics for patients with immune-mediated diseases, today announced that members of its executive team will participate in the upcoming conferences detailed below. GlobeNewsWire 2026-02-05 07:00:00
Climb Bio, Inc. (NASDAQ:CLYM) Receives Average Recommendation of “Moderate Buy” from Brokerages Climb Bio, Inc. (NASDAQ: CLYM - Get Free Report) has been assigned an average recommendation of "Moderate Buy" from the seven ratings firms that are currently covering the firm, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, five have assigned a buy recommendation and one has issued a strong buy recommendation Defense World 2026-01-12 01:28:51
Climb Bio Announces Pipeline Progress and Strategic Priorities for 2026 First patients dosed in budoprutug PrisMN Phase 2 trial in pMN, with initial data expected second half 2026  Dosing ongoing in budoprutug Phase 1b/2a trial in ITP and Phase 1b trial in SLE; achieved regulatory clearance for SLE IND in China First patients dosed in CLYM116 Phase 1 healthy volunteer study Anticipating a data-rich 2026, with initial readouts from all ongoing budoprutug and CLYM116 studies Strong financial position with cash runway expected into 2028 WELLESLEY HILLS, Mass., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical stage biotechnology company developing therapeutics for patients with immune-mediated diseases, today announced progress updates for its budoprutug and CLYM116 programs. GlobeNewsWire 2026-01-08 07:00:00
Ra Capital Management, L.P. Buys 101,462 Shares of Climb Bio (NASDAQ:CLYM) Stock Climb Bio, Inc. (NASDAQ: CLYM - Get Free Report) Director Ra Capital Management, L.P. acquired 101,462 shares of the company's stock in a transaction that occurred on Friday, December 12th. The shares were bought at an average cost of $2.86 per share, for a total transaction of $290,181.32. Following the transaction, the director owned 3,396,318 shares Defense World 2025-12-17 05:26:44
Climb Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) WELLESLEY HILLS, Mass., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases, today announced that Climb Bio has granted an inducement equity award to a new employee, pursuant to the Climb Bio's 2025 Inducement Plan, as amended, as an inducement material to the new employee entering into employment with Climb Bio in accordance with Nasdaq Listing Rule 5635(c)(4). GlobeNewsWire 2025-11-25 07:00:00

Algorithm Performance

Upgrade To Premium for Full Access
Algorithm Profit/Loss Profit Factor # Trades Sharpe Sortino Efficiency
Volume Weighted Momentum Strategy 153.85% 0.38 5 0.1 0.27 106.89
Adaptive Wave 111.82% 2.04 3 0.08 0.21 64.86
Williams PercentR Strategy 99.91% 0.99 338 0.06 0.15 52.94
xxxxxxxxxxxxxxxxxxxx xxxxx% x xxx xxxx xxxx xxxxx
xxxxxxxxxxxxx xxxxxxx% x xxx xxxx xxxx xxxxx
xxxxxxxxxx xxxxxxx% x xxx xxxx xxx xxxxx
xxxxxxxxxxxxxxxxxxxxxxxxxxx xxxxxxx% x xxx xxxx xxxx xxxxx
xxxxxxxxxxxxxxxxxxxxxxxx xxxxxxx% x xx xxxx xxxx xxxxx
xxxxxxxxxxxxxxxxxxxxx xxxxxxx% xxxx xx xxxx xxxx xxxxx
xxxxxxxxxxxxxxxxxx xxxxxxx% xxxx xx xxxx xxxx xxxxx
xxxxxxxxxxxxxxxxxxxxxxxxx xxxxxxx% x xxx xxxx xxxx xxxxx
xxxxxxxxxxxxxx xxxxxxx% x xxx xxxx xxxx xxxx
xxxxxxxxxx xxxxx% xxxx xxx xxxx xxxx xxxxx
xxxxxxxxxxxxxxxxxxxxxxx xxxxxxx% xxxx xxx xxxx xxxx xxxx
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx xxxxxxx% xxxx xxx xxxx xxxx xxxx
xxxxxxxxx xxxxxxx% xxxx xxx xxxx xxxx xxxx
xxxxxxxxxxxxxxx xxxxxxx% xxxx xx xxxx xxxx xxxx
xxxxxxxxxxxxxxxxxxxxxxxxx xxxxxxx% x xx xxxx xxxx xxxx
xxxxxxxxxxxxxxxxx xxxxxxx% xxxx xx xxxx xxxx xxxxx
xxx xxxxxxx% xxxx xxx xxxx xxx xxxxx
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx xxxxxxx% xxxx xxx xxxx xxxx xxxxx
xxxxxxxxxxxxxxxxxxxxx xxxxxxx% xxxx xx xxxx xxxx xxxxx
xxxxxxxxxxxxxxxxxxxxxxxxx xxxxxxx% x xxx xxxx xxxx xxxxx
xxxxxxxxxxxxxxxxxxxxxxxxxxx xxxxxxx% xxxx xx xxxx xxxx xxxxx
xxxxxxxxxxxxxxxxxxxxxxxx xxxxxxx% xxxx xxx xxxx xxxx xxxxx
xxxxxxxxxxxxxxxxxxxxxxx xxxxxxx% x xxx xxxx xxxx xxxxx
xxxxxxxxxxxx xxxxxxx% xxxx xxx x xxxx xxxxx
xxxxxxxxxxxxxxxxxxxxxxx xxxxxxx% xxxx xxx xxxx xxxx xxxxx
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx xxxxxxx% x xxx x xxxx xxxxx
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx x% x xxx x x xxxxx
xxxxxxxxxxxxxxxx xxxxxxxx% x xx x x xxxxx
xxxxxxxxxxxxxxxxxxxxxxxx xxxxxxxx% x xx x x xxxx
xxxxxxxxxxxxxxxxxxxxxxxxxxx xxxxxxxx% x xxx x x xxxxx
xxxx xxxxxxxx% x xxx xxxxx xxxxx xxxxx
xxxxxxxxxxxxxxxxxxxxxx xxxxxxxx% xxxx xxx xxxxx xxxxx xxxx
xxxxxxxxx xxxxxxxx% xxxx xxx xxxxx xxxxx xxxxx
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxx xxxxxxxx% xxxx xxx xxxxx xxxxx xxxxx
xxxxxxxxxxxxxxxxxxxxx xxxxxxxx% x xxx xxxxx xxxxx xxxxx
xxxxxxxxxxxxxxxxxxxxxxxxxxxx xxxxxxxx% x xxx xxxxx xxxxx xxxx
xxxxxxxxx xxxxxxxx% x xxx xxxxx xxxxx xxxx
xxxx xxxxxxxx% x xxx xxxxx xxxxx xxxxx
xxxxxxxxxxxxxxxxxxxx xxxxxxxx% xxxx xxx xxxxx xxxxx xxxxx